cardiology careers collections past issues search home
     

J Am Coll Cardiol, 2007; 50:1373-1380, doi:10.1016/j.jacc.2007.06.047 (Published online 20 August 2007).
© 2007 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
j.jacc.2007.06.047v1
50/14/1373    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schömig, A.
Right arrow Articles by Kastrati, A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Schömig, A.
Right arrow Articles by Kastrati, A.
Related Collections
Right arrowRelated Article

EXPEDITED PUBLICATION

A Meta-Analysis of 16 Randomized Trials of Sirolimus-Eluting Stents Versus Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease

Albert Schömig, MD*,*, Alban Dibra, MD*, Stephan Windecker, MD{dagger}, Julinda Mehilli, MD*, José Suárez de Lezo, MD{ddagger}, Christoph Kaiser, MD§, Seung-Jung Park, MD||, Jean-Jacque Goy, MD{dagger}{dagger}, Jae-Hwan Lee, MD, Emilio Di Lorenzo, MD#, Jinjin Wu, MD*, Peter Jüni, MD**, Matthias E. Pfisterer, MD§, Bernhard Meier, MD{dagger} and Adnan Kastrati, MD*

* Deutsches Herzzentrum, Technische Universität, Munich, Germany
{dagger} Department of Cardiology, University Hospital Bern, Bern, Switzerland
{ddagger} Reina Sofia Hospital, University of Córdoba, Córdoba, Spain
§ University of Basel, Basel, Switzerland
|| Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
Cardiovascular Center in Chungnam National University Hospital, Daejeon, Korea
# A.O.R.N. "S. G. Moscati," Avellino, Italy
** Department of Social and Preventive Medicine, University Hospital Bern, Bern, Switzerland
{dagger}{dagger} Service of Cardiology, Clinique Cecil, Lausanne, Switzerland

Manuscript received May 31, 2007; revised manuscript received June 15, 2007, accepted June 26, 2007.

* Reprint requests and correspondence: Dr. Albert Schömig, Deutsches Herzzentrum, Lazarettstr. 36, 80636 Munich, Germany. (Email: aschoemig{at}dhm.mhn.de).

Objectives: Our purpose was to make a synthesis of the available evidence on the relative efficacy and safety of 2 drug-eluting stents (DES)—sirolimus-eluting stent (SES) and paclitaxel-eluting stent (PES)—in patients with coronary artery disease.

Background: It is not known whether there are differences in late outcomes between the 2 most commonly used DES: SES and PES.

Methods: Sixteen randomized trials of SES versus PES with a total number of 8,695 patients were included in this meta-analysis. A full set of individual outcome data from 5,562 patients was also available. Mean follow-up period ranged from 9 to 37 months. The primary efficacy end point was the need for reintervention (target lesion revascularization). The primary safety end point was stent thrombosis. Secondary end points were death and recurrent myocardial infarction (MI).

Results: No significant heterogeneity was found across trials. Compared with PES, SES significantly reduced the risk of reintervention (hazard ratio [HR] 0.74; 95% confidence interval [CI] 0.63 to 0.87, p < 0.001) and stent thrombosis (HR 0.66; 95% CI 0.46 to 0.94, p = 0.02) without significantly impacting on the risk of death (HR 0.92; 95% CI 0.74 to 1.13, p = 0.43) or MI (HR 0.84; 95% CI 0.69 to 1.03, p = 0.10).

Conclusions: Sirolimus-eluting stents are superior to PES in terms of a significant reduction of the risk of reintervention and stent thrombosis. The risk of death was not significantly different between the 2 DES, but there was a trend toward a higher risk of MI with PES, especially after the first year from the procedure.

Abbreviations and Acronyms
  CI = confidence interval
  DES = drug-eluting stent(s)
  HR = hazard ratio
  MI = myocardial infarction
  PES = paclitaxel-eluting stent(s)
  SES = sirolimus-eluting stent(s)


Related Article

The Emperor’s New Clothes: Another Cypher Versus Taxus Post-Hoc Meta-Analysis
Dean J. Kereiakes
J. Am. Coll. Cardiol. 2007 50: 1381-1385. [Full Text] [PDF]



This article has been cited by other articles:


Home page
Eur Heart JHome page
M. Pfisterer, H. P. Brunner-La Rocca, P. Rickenbacher, P. Hunziker, C. Mueller, F. Nietlispach, G. Leibundgut, F. Bader, C. Kaiser, and for the BASKET Investigators
Long-term benefit-risk balance of drug-eluting vs. bare-metal stents in daily practice: does stent diameter matter? Three-year follow-up of BASKET
Eur. Heart J., November 25, 2008; (2008) ehn516v1.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart J SupplHome page
R. A. Byrne and A. Kastrati
Duration of antiplatelet therapy following intracoronary stenting: are changes needed?
Eur. Heart J. Suppl., November 1, 2008; 10(suppl_I): I25 - I29.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
P. Wenaweser, J. Daemen, M. Zwahlen, R. van Domburg, P. Juni, S. Vaina, G. Hellige, K. Tsuchida, C. Morger, E. Boersma, et al.
Incidence and Correlates of Drug-Eluting Stent Thrombosis in Routine Clinical Practice: 4-Year Results From a Large 2-Institutional Cohort Study
J. Am. Coll. Cardiol., September 30, 2008; 52(14): 1134 - 1140.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
S.-W. Lee, S.-W. Park, Y.-H. Kim, S.-C. Yun, D.-W. Park, C. W. Lee, M.-K. Hong, K.-S. Rhee, J. K. Chae, J.-K. Ko, et al.
A Randomized Comparison of Sirolimus- Versus Paclitaxel-Eluting Stent Implantation in Patients With Diabetes Mellitus
J. Am. Coll. Cardiol., August 26, 2008; 52(9): 727 - 733.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
J. Mehilli, R. A. Byrne, A. Wieczorek, R. Iijima, S. Schulz, O. Bruskina, J. Pache, R. Wessely, A. Schomig, A. Kastrati, et al.
Randomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis
Eur. Heart J., August 2, 2008; 29(16): 1975 - 1982.
[Abstract] [Full Text] [PDF]


Home page
Circ Cardiovasc InterventHome page
M. Takano, M. Yamamoto, D. Murakami, S. Inami, K. Okamatsu, K. Seimiya, T. Ohba, Y. Seino, and K. Mizuno
Lack of Association Between Large Angiographic Late Loss and Low Risk of In-Stent Thrombus: Angioscopic Comparison Between Paclitaxel- and Sirolimus-Eluting Stents
Circ Cardiovasc Intervent, August 1, 2008; 1(1): 20 - 27.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
S. R. Dixon, C. L. Grines, and W. W. O'Neill
The year in interventional cardiology.
J. Am. Coll. Cardiol., June 17, 2008; 51(24): 2355 - 2369.
[Full Text] [PDF]


Home page
JAMAHome page
A. M. Galloe, L. Thuesen, H. Kelbaek, P. Thayssen, K. Rasmussen, P. R. Hansen, N. Bligaard, K. Saunamaki, A. Junker, J. Aaroe, et al.
Comparison of Paclitaxel- and Sirolimus-Eluting Stents in Everyday Clinical Practice: The SORT OUT II Randomized Trial
JAMA, January 30, 2008; 299(4): 409 - 416.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
D. Mukherjee and D. J. Moliterno
Effectiveness of Drug-Eluting Stents in Real-World Patients
JAMA, January 30, 2008; 299(4): 454 - 455.
[Full Text] [PDF]


Home page
Journal Watch CardiologyHome page
Sirolimus-Eluting vs. Paclitaxel-Eluting Stents: A Meta-Analysis
Journal Watch Cardiology, October 3, 2007; 2007(1003): 3 - 3.
[Full Text]


Home page
J Am Coll CardiolHome page
D. J. Kereiakes
The Emperor's New Clothes: Another Cypher Versus Taxus Post-Hoc Meta-Analysis
J. Am. Coll. Cardiol., October 2, 2007; 50(14): 1381 - 1385.
[Full Text] [PDF]



 
  cardiology careers collections past issues search home